Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
The latest announcement is out from Mereo Biopharma Group Plc ( (MREO) ).
On August 11, 2026, Mereo BioPharma entered into an option and license agreement granting Sentynl Therapeutics U.S. commercial and global manufacturing rights to alvelestat for alpha‑1 antitrypsin deficiency‑associated lung disease, a rare genetic respiratory disorder. Under the deal, Mereo receives a non‑refundable option fee and, if Sentynl exercises the option, is eligible for $40 million in upfront and R&D payments, up to $435 million in milestones and double‑digit tiered royalties on U.S. sales.
Mereo will lead the global Phase 3 program and regulatory interactions for alvelestat, while collaborating with Sentynl during a short option period to refine trial design and advance manufacturing, with Phase 3 potentially starting in early 2027. The agreement deepens Mereo’s capital‑light, partnership‑based strategy in rare diseases, positions alvelestat as a potential first‑in‑class oral therapy for a U.S. patient population estimated at 50,000–80,000, and further expands Sentynl’s rare disease portfolio and U.S. commercial footprint.
The most recent analyst rating on (MREO) stock is a Buy
with a $3.00 price target.
To see the full list of analyst forecasts on Mereo Biopharma Group Plc stock,
see the MREO Stock Forecast page.
Spark’s Take on MREO Stock
According to Spark, TipRanks’ AI Analyst, MREO is a Neutral.
The score is primarily held down by weak financial performance—large losses, minimal revenue, and continued cash burn—despite a low-debt balance sheet. Technicals show only modest near-term improvement with the longer-term trend still weak, and valuation remains constrained by negative earnings and no dividend support. Corporate actions add financing flexibility but also underscore potential dilution risk.
To see Spark’s full report on MREO stock,
click here.
More about Mereo Biopharma Group Plc
Mereo BioPharma Group plc is a clinical‑stage biopharmaceutical company focused on developing innovative therapeutics for rare diseases, with a pipeline that includes setrusumab for osteogenesis imperfecta, alvelestat for alpha‑1 antitrypsin deficiency‑associated lung disease (AATD‑LD), and vantictumab for autosomal dominant osteopetrosis type 2. The company operates through a partnership-driven model, retaining selected regional commercial rights while collaborators such as Ultragenyx, Sentynl and āshibio fund and lead global development of key assets.
Average Trading Volume: 3,126,394
Technical Sentiment Signal: Sell
Current Market Cap: $47.29M
For an in-depth examination of MREO stock, go to TipRanks’ Overview page.